metformin/rosiglitazone

Action and Spectrum

Actions and Spectrum: 

metformin and rosiglitazone are commonly used medications for managing type 2 diabetes mellitus. They have different mechanisms of action and target different aspects of glucose metabolism.  

metformin: 

Action: metformin primarily reduces liver hepatic glucose production (gluconeogenesis). It also enhances insulin sensitivity in peripheral tissues, such as muscle and fat, which leads to improved glucose uptake and utilization. Spectrum of Action: metformin effectively reduces blood glucose levels in individuals with type 2 diabetes.

It is usually prescribed as a first-line treatment for the condition and can be used as monotherapy or combined with other oral antidiabetic medications or insulin. metformin is also associated with beneficial effects on weight loss, lipid profiles, and cardiovascular outcomes. 

rosiglitazone: 

Action: rosiglitazone belongs to a class of drugs called thiazolidinediones (TZDs) or glitazones. It primarily acts as a peroxisome proliferator-activated receptor-gamma (PPARγ) agonist. PPARγ is a nuclear receptor involved in regulating glucose and lipid metabolism. Activation of PPARγ improves insulin sensitivity in adipose tissue, skeletal muscle, and liver, resulting in increased glucose uptake and decreased hepatic glucose production. 

The Spectrum of Action: rosiglitazone is also used to manage type 2 diabetes, typically as a second or third-line agent when other treatments have not adequately controlled blood sugar levels. It can be used as monotherapy or in combination with other antidiabetic medications, including metformin or sulfonylureas. However, rosiglitazone has become more restricted due to concerns regarding cardiovascular safety. 

Drug Interaction

Adverse Reaction

Frequency defined 

>10% 

Hypoglycemia (12%) 

Upper respiratory tract infections (16-20%) 

Edema (6% to 25%) 

Diarrhea (12.7% to 14%) 

1-10% 

Sinusitis (6%) 

Viral infection (5%) 

Back pain (5%) 

Fatigue (6%) 

Headache (6%) 

Arthralgia (5%) 

Anemia (4% to 7%) 

Frequency not defined 

Death from cardiovascular causes 

Congestive heart failure 

Diabetic macular edema 

Pulmonary edema 

Pleural effusion 

Angioedema (Infrequent) 

Anaphylaxis (Infrequent) 

Stevens-Johnson syndrome (Infrequent) 

Lactic acidosis (Infrequent) 

Hepatotoxicity (Infrequent) 

Black Box Warning

Black Box Warning: 

metformin carries a black box warning of lactic acidosis, a rare but severe condition characterized by lactic acid buildup in the body. This risk is higher in individuals with impaired kidney function, liver disease, or those who experience severe dehydration or conditions that can lead to tissue hypoxia.  

rosiglitazone carries a black box warning for an increased risk of congestive heart failure (CHF). It is contraindicated in patients with established CHF or a history of CHF and should be used cautiously in individuals with pre-existing cardiac conditions.  

Contraindication / Caution

Contraindication/Caution: 

Contraindication 

metformin: 

• Renal Impairment: metformin is contraindicated in individuals with severe renal impairment (estimated glomerular filtration rate [eGFR] below 30 mL/min/1.73 m²) due to the increased risk of lactic acidosis. It should be used cautiously in patients with mild to moderate renal impairment (eGFR between 30-59 mL/min/1.73 m²). 
• Hepatic Impairment: metformin should be avoided in patients with acute or chronic liver disease as it can potentially contribute to developing lactic acidosis. 
• Metabolic Acidosis: metformin is contraindicated in individuals with metabolic acidosis, including diabetic ketoacidosis, as it can exacerbate the condition. 
• Hypersensitivity: It is contraindicated in patients with known hypersensitivity or allergy to metformin. 

rosiglitazone: 

• Congestive Heart Failure: rosiglitazone is contraindicated in patients with an established history of heart failure. It can worsen fluid retention and lead to cardiovascular complications. 
• Severe Hepatic Impairment: It is contraindicated in individuals with severe hepatic impairment, including those with elevated liver enzymes. 
• Hypersensitivity: rosiglitazone should not be used in patients with known hypersensitivity or allergy to rosiglitazone or other thiazolidinediones. 
• Pregnancy: It is contraindicated during pregnancy or in women of childbearing potential condition who are not using effective contraception, as it may cause harm to the fetus. 

Caution 

metformin: 

• Renal Impairment: metformin should be used cautiously in patients with mild-moderate renal impairment (eGFR between 30-59 mL/min/1.73 m²). The dose may need to be adjusted based on renal function, and close monitoring is necessary to prevent the risk of lactic acidosis. 
• Hepatic Impairment: metformin should be used cautiously in individuals with hepatic impairment, as it can potentially contribute to developing lactic acidosis. Regular liver function tests may be required. 
• Heart Failure: metformin should be used cautiously in patients with a history of heart failure or other conditions that may increase the risk of fluid retention.  
• Hypoxic Conditions: metformin should be used cautiously in patients with conditions that can lead to tissue hypoxia, such as severe acute illness, sepsis, or respiratory failure. These conditions may increase the risk of lactic acidosis. 
• Surgery and Radiological Studies: metformin is typically withheld temporarily in patients undergoing major surgery or radiological procedures involving contrast agents due to the potential risk of lactic acidosis.  

rosiglitazone: 

• Cardiovascular Risk: rosiglitazone has been associated with an enhanced risk of cardiovascular events, including myocardial infarction. It should be used cautiously in patients with a history of cardiovascular disease or those at an increased risk of cardiovascular events. Regular cardiovascular monitoring is recommended. 
• Liver Function: Regular liver function tests are recommended when using rosiglitazone due to the potential risk of hepatotoxicity. 
• Edema and Weight Gain: rosiglitazone can cause fluid retention and weight gain. It should be used with caution in patients with a history of edema or heart failure, and careful monitoring of fluid status is necessary. 
• Fracture Risk: There is evidence suggesting an increased risk of fractures, particularly in women, with the use of rosiglitazone. This should be considered when prescribing the medication, especially in patients with a history of osteoporosis or increased fracture risk. 
• Macular Edema: There have been reports of macular edema using rosiglitazone. Regular ophthalmic monitoring is recommended in at-risk patients or those with existing macular edema. 

Pregnancy / Lactation

Pregnancy consideration:  

US FDA pregnancy category: C 

Lactation:   

Excreted into human milk: Not known. 

Pregnancy category: 

• Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester. 
• Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women. 
• Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.    
• Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.    
• Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.    
• Category N: There is no data available for the drug under this category 

Pharmacology

Pharmacology: 

metformin and rosiglitazone are antidiabetic medications with different pharmacological mechanisms. metformin primarily inhibits hepatic gluconeogenesis, reduces glucose production in the liver, and enhances peripheral insulin sensitivity, thereby increasing glucose uptake and utilization in tissues. It activates AMP-activated protein kinase (AMPK) and inhibits mitochondrial glycerophosphate dehydrogenase, leading to altered cellular energy metabolism.

metformin also has indirect effects on gut hormone secretion and intestinal glucose absorption. On the other hand, rosiglitazone is a peroxisome proliferator-activated receptor-gamma (PPARγ) agonist that modulates gene transcription, enhancing insulin sensitivity in adipose tissue, skeletal muscle, and liver. This activation of PPARγ regulates adipogenesis, fatty acid uptake, and glucose metabolism, resulting in improved glucose uptake and utilization in peripheral tissues. 

Pharmacodynamics: 

Mechanism of action: The action of metformin and rosiglitazone in the therapy of type 2 diabetes differs: 

metformin: metformin exerts its anti-diabetic effects through multiple mechanisms, although the exact mechanism of action is not fully understood.  

• Inhibition of Hepatic Gluconeogenesis: metformin suppresses glucose production in the liver by inhibiting hepatic gluconeogenesis, the process by which the liver produces glucose. It reduces the expression of enzymes involved in gluconeogenesis, decreasing the amount of glucose released into the bloodstream. 
• Enhanced Insulin Sensitivity: metformin improves insulin sensitivity in peripheral tissues like skeletal muscle and adipose tissue. It enhances these tissues’ uptake and utilization of glucose, promoting its clearance from the bloodstream. 
• Activation of AMP-activated Protein Kinase (AMPK): metformin activates an enzyme called AMP-activated protein kinase (AMPK), which plays a important role in cellular energy metabolism. Activation of AMPK leads to increased glucose uptake, fatty acid oxidation, and inhibition of cellular processes that consume energy. 
• Modulation of Gut Hormone Secretion: metformin has been shown to affect gut hormone secretion, such as glucagon-like peptide-1 (GLP-1). These hormones regulate glucose metabolism and appetite, contributing to the overall glucose-lowering effect of metformin. 

rosiglitazone: rosiglitazone belongs to a class of medications called thiazolidinediones (TZDs) or glitazones. Its mechanism of action involves the activation of peroxisome proliferator-activated receptor-gamma (PPARγ), a nuclear receptor that regulates gene expression.  

• Improved Insulin Sensitivity: rosiglitazone enhances insulin sensitivity in peripheral tissues, like adipose tissue, skeletal muscle, and liver. Activation of PPARγ by rosiglitazone alters the expression of genes involved in the glucose and lipid metabolism, leading to increased glucose uptake and utilization in these tissues. 
• Modulation of Adipogenesis: rosiglitazone promotes adipogenesis, the pre-adipocytes’ differentiation into mature adipocytes. This results in increased adipose tissue mass and improved insulin sensitivity. 
• Regulation of Glucose and Lipid Metabolism: rosiglitazone influences the expression of genes involved in the glucose and lipid metabolism, reducing hepatic glucose production and increasing peripheral glucose uptake. 

Pharmacokinetics: 

Absorption 

metformin is well absorbed from the gastrointestinal tract after oral administration. Its absorption takes place mainly in the upper part of the small intestine. 

rosiglitazone is well absorbed after oral administration, with peak plasma concentrations reached within 1 to 2 hours. Its absorption is not significantly affected by food. 

Distribution 

metformin has a relatively low protein binding (less than 5%) and distributes predominantly into tissues. It has a large volume of distribution, indicating extensive tissue distribution. 

rosiglitazone is highly protein-bound (over 99%) to plasma proteins, primarily to albumin. It distributes extensively into adipose tissue, liver, and muscle. 

Metabolism 

metformin is not significantly metabolized in the liver. It is primarily eliminated unchanged in the urine. rosiglitazone undergoes extensive hepatic metabolism via cytochrome P450 enzymes, primarily CYP2C8 and, to a lesser extent, CYP2C9. The significant metabolites formed are inactive. 

Elimination and Excretion 

metformin is primarily excreted unchanged in the urine by active tubular secretion. It is not significantly eliminated via feces. The metabolites of rosiglitazone are excreted in the urine and feces. Most of the administered dose is eliminated in the feces, with less than 1% excreted unchanged in the urine. 

Adminstartion

Administration: 

Oral administration 

metformin and rosiglitazone are both oral medications that are typically taken by mouth.  

metformin: 

• Dosage: metformin is available in various strengths (typically 500 mg, 850 mg, and 1000 mg). The dose and frequency of metformin can vary depending on the individual’s condition and response to treatment. It is usually taken twice to three times daily with meals to reduce gastrointestinal side effects. 
• Extended-Release Formulation: metformin is also available in an extended-release (ER) formulation, which allows for once-daily dosing. The ER formulation should be swallowed whole and not crushed or chewed. 
• Dosing Adjustment: The metformin dose may need to be adjusted based on factors such as renal function, tolerability, and glycemic control. Close monitoring of blood glucose levels and regular follow-ups with a healthcare professional is essential to determine the appropriate dose. 
• Combination Therapy: metformin is often used in combination with other antidiabetic medications, such as sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, or sodium-glucose co-transporter 2 (SGLT2) inhibitors. The specific dosing and administration instructions for combination therapy will depend on the prescribed regimen. 

rosiglitazone: 

• Dosage: rosiglitazone is available in tablet form in various strengths (typically 2 mg and 4 mg). The healthcare professional will determine the dose and frequency of rosiglitazone based on individual factors, including glycemic control and tolerability. 
• Administration: rosiglitazone is usually taken once or twice daily, with or without meals. Following the prescribed dosing instructions the healthcare professional provides or indicates on the medication label is essential. 
• Combination Therapy: rosiglitazone is often used with other antidiabetic medications, such as metformin or sulfonylureas. The specific dosing and administration instructions for combination therapy will depend on the prescribed regimen. 

Patient Information Leaflet

Patient information leaflet 

Generic Name: metformin/rosiglitazone 

Pronounced: [ met-FOR-min-hye-droe-KLOR-ide, roe-zi-GLI-ta-zone-MAL-ee-ate ] 

Why do we use metformin/rosiglitazone? 

metformin and rosiglitazone are both medications used to manage type 2 diabetes mellitus.  

metformin: 

• Type 2 Diabetes: metformin is commonly prescribed as a first-line treatment for type 2 diabetes. It helps to decrease blood glucose levels by reducing hepatic glucose production (gluconeogenesis) and enhancing insulin sensitivity in peripheral tissues. metformin can be used as monotherapy/in combination with other oral antidiabetic medications or insulin to achieve glycemic control. 

rosiglitazone: 

• Type 2 Diabetes: rosiglitazone also manages type 2 diabetes. It belongs to a class of medications known as thiazolidinediones (TZDs) or glitazones. rosiglitazone primarily acts as a peroxisome proliferator-activated receptor-gamma (PPARγ) agonist, improving insulin sensitivity in adipose tissue, skeletal muscle, and liver. It can be used as monotherapy or in combination with other antidiabetic medications to help control blood glucose levels.